Corporate GovernanceSep 29, 2026, 04:07 PM
ANGIOGENICS INC Files 10-K Amendment for XBRL Tagging
AI Summary
ANGIOGENICS INC (ANGO) has filed an amendment to its 2026 Form 10-K, primarily to add XBRL tagging to Part III information. The filing confirms ANGO's status as an accelerated filer and details the composition and committee memberships of its Board of Directors. It also outlines the company's executive compensation philosophy, emphasizing performance-based pay, and reiterates its Insider Trading Policy. Deloitte & Touche LLP is listed as the auditor.
Key Highlights
- ANGIOGENICS INC (ANGO) files Amendment to its 2026 Form 10-K to include XBRL tagging for Part III.
- The company confirms it is an accelerated filer and not a smaller reporting company or emerging growth company.
- Deloitte & Touche LLP serves as the auditor.
- The Board of Directors consists of eight members, with staggered three-year terms.
- The Audit Committee has an independent financial expert, Wesley E. Johnson, Jr.
- The Compensation and Human Capital Committee comprises independent directors.
- Executive compensation is heavily performance-based, with 64% of CEO's target compensation being performance-based in FY2026.
- The company's Insider Trading Policy prohibits hedging, monetization, and pledging of company securities.
Price Impact
More from ANGO